# GP Extended Action Triptorelin

> **NCT01673984** · PHASE4 · TERMINATED · sponsor: **Ipsen** · enrollment: 27 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Decapeptyl® SR 22.5mg
- **DRUG:** Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg

## Key facts

- **NCT ID:** NCT01673984
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The study was discontinued prematurely by the sponsor due to non-medical reasons
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673984, "GP Extended Action Triptorelin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01673984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*